
===== DOI 10.1056/NEJMoa2506765 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41337735</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>393</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Noninferiority of One HPV Vaccine Dose to Two Doses.</ArticleTitle><Pagination><StartPage>2421</StartPage><EndPage>2433</EndPage><MedlinePgn>2421-2433</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2506765</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multidose human papillomavirus (HPV) vaccination is efficacious, yet the vaccine has been underused globally. Emerging data suggest that a single dose may provide protection. Whether a single dose of HPV vaccine would provide similar protection to two doses is uncertain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this trial, we assessed whether one dose of an HPV vaccine was noninferior to two doses. Girls 12 to 16 years of age were randomly assigned, in a 1:1:1:1 ratio, to receive one or two doses of a bivalent HPV vaccine or one or two doses of a nonavalent HPV vaccine. The primary end point was new HPV type 16 or 18 infection occurring from month 12 to month 60 and persisting for at least 6 months. The prespecified noninferiority margin was 1.25 infections per 100 participants. We also assessed vaccine effectiveness by comparing HPV16 or HPV18 infection among the trial participants with that among girls and women enrolled in a nonrandomized survey.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 20,330 participants were enrolled and underwent randomization, and 3005 unvaccinated participants were enrolled in the survey. The noninferiority analysis showed that one vaccine dose was noninferior to two doses in preventing HPV16 or HPV18 infection. The rate difference between one and two doses of the bivalent vaccine was -0.13 infections per 100 participants (95% confidence interval [CI], -0.45 to 0.15; P&lt;0.001 for noninferiority), and the difference between one and two doses of the nonavalent vaccine was 0.21 infections per 100 participants (95% CI, -0.09 to 0.51; P&lt;0.001 for noninferiority). The vaccine effectiveness was at least 97% in each of the four trial groups. No safety concerns were identified.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">One dose of either a bivalent or nonavalent HPV vaccine provided protection against HPV16 or HPV18 infection and was not inferior to two doses. (Funded by the National Cancer Institute and others; ESCUDDO ClinicalTrials.gov number, NCT03180034.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kreimer</LastName><ForeName>Aim&#xe9;e R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Danping</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildesheim</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvajal</LastName><ForeName>Loretto J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocampo</LastName><ForeName>Rebeca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero</LastName><ForeName>Byron</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gail</LastName><ForeName>Mitchell H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes</LastName><ForeName>Bernal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sierra</LastName><ForeName>Monica S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-1286-057X</Identifier><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coronado</LastName><ForeName>Karla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coto</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagnall</LastName><ForeName>Casey L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Cancer Genomics Research Laboratory, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemp</LastName><ForeName>Troy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuniga</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Ligia A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrientos</LastName><ForeName>Gloriana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schussler</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Information Management Services, Silver Spring, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Yenory</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montero</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avila</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggieri</LastName><ForeName>Dave</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Information Management Services, Silver Spring, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cyr</LastName><ForeName>Jean T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Information Management Services, Silver Spring, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chanock</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowy</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Center for Cancer Research, National Cancer Institute, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiller</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Center for Cancer Research, National Cancer Institute, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrero</LastName><ForeName>Rolando</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biom&#xe9;dicas, Fundaci&#xf3;n INCIENSA, San Jos&#xe9;, Costa Rica.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Agency for Research on Cancer, World Health Organization, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03180034</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D000073843">Equivalence Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053918">Papillomavirus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052162" MajorTopicYN="Y">Human papillomavirus 16</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052161" MajorTopicYN="Y">Human papillomavirus 18</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053918" MajorTopicYN="Y">Papillomavirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="Y">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>16</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41337735</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2506765</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00616-3 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41308684</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Misclassification of p16-positive, HPV-negative patients biases de-escalation trials.</ArticleTitle><Pagination><StartPage>e623</StartPage><MedlinePgn>e623</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00616-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00616-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lovett</LastName><ForeName>Jessica T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA. Electronic address: jessica.lovett@nyulangone.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wotman</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posner</LastName><ForeName>Marshall</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tampa General Hospital Cancer Institute/Cancer Center of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41308684</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00616-3</ArticleId><ArticleId IdType="pii">S1470-2045(25)00616-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00655-2 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41308685</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Misclassification of p16-positive, HPV-negative patients biases de-escalation trials - Authors' reply.</ArticleTitle><Pagination><StartPage>e624</StartPage><MedlinePgn>e624</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00655-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00655-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Routman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Anatomic Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: ma.daniel@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>DMR reports funding from the Paul Calabresi Program in Clinical/Translational Research (K12CA090628), licensing with EXACT sciences, and presentations with Adela Biosciences, none of which were involved in the trial. DJM reports intellectual property with EXACT Sciences, In Situ Biologics, and CurrentHealth, none of which were involved in the trial. JSL declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41308685</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00655-2</ArticleId><ArticleId IdType="pii">S1470-2045(25)00655-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>